|1.||Nah, Deuk-Young: 1 article (05/2015)|
|2.||Moon, Il Soo: 1 article (05/2015)|
|3.||Bae, Jun-Ho: 1 article (05/2015)|
|4.||Chun, Woo-Jung: 1 article (05/2015)|
|5.||Chung, Jin-Wook: 1 article (05/2015)|
|6.||Lee, HyunSook: 1 article (05/2015)|
|7.||Yoo, Y-C: 1 article (01/2013)|
|8.||Gerc, Vjekoslav: 1 article (01/2013)|
|9.||Kacila, Mirsad: 1 article (01/2013)|
|10.||Faruk, Custovic: 1 article (01/2013)|
06/01/2005 - "Larger multicenter trials need to resolve the questions on the efficiency of metabolic intervention with GIK solution in acute myocardial infarction."
06/01/2005 - "The GIK solution decreased the incidence of new-onset symptomatic congestive heart failure and low HRV after myocardial infarction. "
08/01/2002 - "GIK solution therapy achieved NEFA suppression and an insignificant trend toward reduced biochemical parameters of ischemic injury in OP-CAB surgery and CPB groups, but no major clinical benefit (perioperative myocardial infarction, intensive care unit length of stay, or hospital length of stay) was shown after elective CABG surgery in low-risk patients. "
07/01/2010 - "To evaluate the effects of high-dose glucose-insulin-potassium (GIK) solution on hemodynamics and cardiac remodeling in patients with acute myocardial infarction (AMI) treated with primary percutaneous coronary intervention (PCI). "
09/01/2007 - "Glucose-insulin-potassium (GIK) solution was primarily used in myocardial infarction. "
08/01/1993 - "The efficacy of myocardial preservation using GIK solution combined with continuous cold blood perfusion was assessed in patients with prolonged ischemia. "
08/01/1993 - "In conclusion, postoperative cardiac function after 4 hours' ischemia using GIK solution deteriorated in the patients with a dilated heart due to aortic regurgitation."
05/01/2015 - "We established a neonatal rat ventricular myocyte (NRVM) in vitro coverslip ischemia/reperfusion (I/R) model and investigated the effects of GIK solution on suppressing reactive oxygen species (ROS) and upregulating O-GlcNacylation, which protects cells from ischemic injury. "
09/01/2003 - "Fifty male Sprague-Dawley rats (200-225 g) were divided into 5 groups each containing 10 rats; group SO, sham operation group; group I, mesenteric ischemia group (for 30 minutes); group R, ischemia plus reperfusion (for 60 minutes); group BR, ischemia-reperfusion plus BN 52021; group GR, ischemia-reperfusion plus GIK solution. "
09/01/2012 - "From the beginning of ischemia, the perfusate was subjected to various changes: enrichment with GIK solution, enrichment with lactate (2 mM), enrichment with pyruvate (2 mM), enrichment with pyruvate (2 mM) plus ethanol (2 mM), or no change for the control group. "
|3.||Heart Arrest (Cardiac Arrest)
06/01/1998 - "Cardiac arrest was then obtained with a cold GIK solution. "
01/01/1982 - "These data suggest that Mg-lidocaine-1-aspartate solution is superior to GIK solution as a cardioplegic solution, and that such will feasibly provide myocardial protection for 2 hours of hypothermic cardiac arrest, in an experimental reperfused model."
09/01/1999 - "Coronary vascular beds of the dog were washed out with a University of Wisconsin (UW) solution following cardiac arrest obtained using a GIK solution. "
12/01/1999 - "In the UW group (n = 7), UW solution at 4 degrees C was used for coronary vascular washout and storage following cardiac arrest with glucose-insulin-potassium (GIK) solution. "
01/01/1991 - "(p less than 0.05) 4) Fluctuations in the nucleotide level indicated that the current method of myocardial protection using GIK solution produced unsatisfactory recover from ischemic damage and reperfusion injury."
09/01/2003 - "These observations suggest that treatment with GIK solution and BN 52021 before reperfusion and during reperfusion period may be useful in decreasing intestinal reperfusion injury."
09/01/2003 - "The objective of this study was to investigate effects of glucose-insulin-potassium (GIK) solution and BN 52021, a platelet-activating factor antagonist, on intestinal ischemia-reperfusion injury. "
|5.||Platelet Activating Factor
|7.||University of Wisconsin-lactobionate solution
|9.||Pyruvic Acid (Pyruvate)
|1.||Off-Pump Coronary Artery Bypass (Coronary Artery Bypass, Off Pump)
|2.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
|3.||Length of Stay